首页> 外文期刊>Journal of Medicinal Chemistry >Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase
【24h】

Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase

机译:具有质子偶联的叶酸转运蛋白和叶酸受体选择性的高效6-取代的吡咯并[2,3-d]嘧啶硫代酰基噻吩基抗叶酸抑制剂的合成,生物学和抗肿瘤活性超过了抑制β-甘氨酰胺核糖核苷酸甲酰基转移酶的叶酸载体

获取原文
获取原文并翻译 | 示例
       

摘要

2-Amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine antifolates with a thienoyl side chain (compounds 1-3, respectively) were synthesized for comparison with compound 4, the previous lead compound of this series. Conversion of hydroxyl acetylen-thiophene carboxylic esters to thiophenyl-α-bromomethylketones and condensation with 2,4-diamino-6- hydroxypyrimidine afforded the 6-substituted pyrrolo[2,3-d]pyrimidine compounds of type 18 and 19. Coupling with l-glutamate diethyl ester, followed by saponification, afforded 1-3. Compound 3 selectively inhibited the proliferation of cells expressing folate receptors (FRs) α or β, or the proton-coupled folate transporter (PCFT), including KB and IGROV1 human tumor cells, much more potently than 4. Compound 3 was more inhibitory than 4 toward β-glycinamide ribonucleotide formyltransferase (GARFTase). Both 3 and 4 depleted cellular ATP pools. In SCID mice with IGROV1 tumors, 3 was more efficacious than 4. Collectively, our results show potent antitumor activity for 3 in vitro and in vivo, associated with its selective membrane transport by FRs and PCFT over RFC and inhibition of GARFTase, clearly establishing the 3-atom bridge as superior to the 1-, 2-, and 4-atom bridge lengths for the activity of this series.
机译:合成了具有噻吩基侧链的2-氨基-4-氧代-6-取代的吡咯并[2,3-d]嘧啶抗叶酸酯(分别为化合物1-3),以与化合物4(该系列先前的先导化合物)进行比较。将羟基乙炔-噻吩羧酸酯转化为硫代苯基-α-溴甲基酮,并与2,4-二氨基-6-羟基嘧啶缩合,得到18和19型的6-取代吡咯并[2,3-d]嘧啶化合物。 -谷氨酸二乙酯,然后皂化,得到1-3。化合物3选择性抑制表达叶酸受体(FRs)α或β或质子偶联叶酸转运蛋白(PCFT)的细胞(包括KB和IGROV1人肿瘤细胞)的增殖,其抑制作用远强于4种。化合物3抑制作用大于4种朝向β-甘氨酰胺核糖核苷酸甲酰基转移酶(GARFTase)。 3和4耗尽了细胞ATP池。在具有IGROV1肿瘤的SCID小鼠中,3个比4个更有效。总体而言,我们的结果显示,3个在体内和体外均具有强​​大的抗肿瘤活性,与FRs和PCFT对RFC的选择性膜转运以及对GARFTase的抑制有关,从而明显地建立了3原子桥比1、2和4原子桥的长度要好于该系列的活性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号